GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side

GARDASIL (Merck, Whitehouse Station, NJ) is a non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid proteins of human papillomavirus (HPV) types 6, 11, 16, and 18. GARDASIL is the first vaccine approved for use in women age...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacology and therapeutics Vol. 81; no. 2; p. 259
Main Authors Shi, L, Sings, H L, Bryan, J T, Wang, B, Wang, Y, Mach, H, Kosinski, M, Washabaugh, M W, Sitrin, R, Barr, E
Format Journal Article
LanguageEnglish
Published United States 01.02.2007
Subjects
Adolescent
Adult
Alphapapillomavirus - immunology
Animals
Child
Clinical Trials as Topic
Drug Evaluation, Preclinical - methods
Female
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Humans
Papillomavirus Infections - immunology
Papillomavirus Infections - prevention & control
Papillomavirus Infections - virology
Papillomavirus Vaccines - administration & dosage
Papillomavirus Vaccines - immunology
Online AccessGet more information

Cover

More Information
Summary:GARDASIL (Merck, Whitehouse Station, NJ) is a non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid proteins of human papillomavirus (HPV) types 6, 11, 16, and 18. GARDASIL is the first vaccine approved for use in women aged 9-26 years for the prevention of cervical cancer and genital warts, as well as vulvar and vaginal precancerous lesions. This report describes some of the key preclinical efforts, achievements in pharmaceutical development, in vivo animal evaluation, and clinical trial data.
ISSN:0009-9236
DOI:10.1038/sj.clpt.6100055